← Trials/Trial dossier/NCT03498001

LICAS-MR

CompletedPhase NA

Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging

Lead sponsor

Centre Hospitalier Universitaire Dijon

Assets

Dulaglutide / Liraglutide / Semaglutide

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI ≥30•HbA1c ≥7%

Primary endpoint

•Change from Baseline Concentration of intramyocardial triglycerides

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03498001

Org study IDGUENANCIA APJ 2016

Timeline

Milestones

Study first posted2018-04-13actual

Study start2018-04-16actual

Primary completion2023-06-06actual

Study completion2023-12-20actual

Last update posted2026-02-04actual

Assets

Investigational agents

Dulaglutide Liraglutide Semaglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age50 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Patient who has given his consent

•Adult patient over 50 years of age Type II diabetic treated without modification of the antidiabetic treatment during the previous 3 months

•HbA1c ≥ 7%.

•Patient for whom a decision to start a GLP-1 agonist treatment has been made (Liraglutide, Semaglutide, Dulaglutide).

•At least one risk factor from among:

•Treated hypertension,

•treated dyslipidemia,

•History of obesity (BMI>30 kg/m2)

•Active smoking (from 1 cigarette per day) or smoking cessation for less than 3 years,

•Coronary heredity (myocardial infarction or sudden death before age 55 in father/brother, myocardial infarction or sudden death before age 65 in mother/sister)

Exclusion criteria

- Protected adult Patient not affiliated to a national health insurance scheme Pregnant or breastfeeding woman Women who intend to become pregnant or of childbearing age and do not use adequate contraceptive methods.

Antidiabetic treatment of the incretin family (DPP4 inhibitor except sitagliptin) Severe renal failure (clearance <30ml/min according to Cockroft due to gadolinium injection) Claustrophobia / contraindication to MRI (compatible non-MRI implanted metallic material) History of hypersensitivity to gadoteric acid or gadolinium-based contrast agents and meglumine Hypersensitivity to Liraglutide, Semaglutide, Dulaglutide or any of the excipients History or presence of pancreatitis (acute or chronic) Chronic inflammatory bowel disease Diabetic gastroparesis Dysthyroidism

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Change from Baseline Concentration of intramyocardial triglycerides at 6 months

Time frame:Month 6

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Evolution of myocardial steatosis in high cardiovascular risk T2DM patients treated by GLP1 receptor agonists: LICAS study.
Diabetes research and clinical practice2025 Mar (month)PMID39900263doi:10.1016/j.diabres.2025.112017via CT.gov reference

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.